227 related articles for article (PubMed ID: 21097672)
1. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.
Moreaux J; Hose D; Kassambara A; Reme T; Moine P; Requirand G; Goldschmidt H; Klein B
Blood; 2011 Jan; 117(4):1280-90. PubMed ID: 21097672
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome profiling of osteoclast subsets associated with arthritis: A pathogenic role of CCR2
Filipović M; Flegar D; Aničić S; Šisl D; Kelava T; Kovačić N; Šućur A; Grčević D
Front Immunol; 2022; 13():994035. PubMed ID: 36591261
[TBL] [Abstract][Full Text] [Related]
3. Preventive CCL2/CCR2 Axis Blockade Suppresses Osteoclast Activity in a Mouse Model of Rheumatoid Arthritis by Reducing Homing of CCR2
Flegar D; Filipović M; Šućur A; Markotić A; Lukač N; Šisl D; Ikić Matijašević M; Jajić Z; Kelava T; Katavić V; Kovačić N; Grčević D
Front Immunol; 2021; 12():767231. PubMed ID: 34925336
[TBL] [Abstract][Full Text] [Related]
4. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
5. Osteoclast function in Paget's disease and multiple myeloma.
Roodman GD
Bone; 1995 Aug; 17(2 Suppl):57S-61S. PubMed ID: 8579899
[TBL] [Abstract][Full Text] [Related]
6. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
[TBL] [Abstract][Full Text] [Related]
7. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.
Lu Y; Chen Q; Corey E; Xie W; Fan J; Mizokami A; Zhang J
Clin Exp Metastasis; 2009; 26(2):161-9. PubMed ID: 19002595
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
Pennisi A; Li X; Ling W; Khan S; Gaddy D; Suva LJ; Barlogie B; Shaughnessy JD; Aziz N; Yaccoby S
Br J Haematol; 2009 Jun; 145(6):775-87. PubMed ID: 19388929
[TBL] [Abstract][Full Text] [Related]
10. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
11. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
12. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.
He J; Liu Z; Zheng Y; Qian J; Li H; Lu Y; Xu J; Hong B; Zhang M; Lin P; Cai Z; Orlowski RZ; Kwak LW; Yi Q; Yang J
Cancer Res; 2012 Dec; 72(24):6393-402. PubMed ID: 23066034
[TBL] [Abstract][Full Text] [Related]
13.
Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
[TBL] [Abstract][Full Text] [Related]
14. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.
Feng R; Anderson G; Xiao G; Elliott G; Leoni L; Mapara MY; Roodman GD; Lentzsch S
Blood; 2007 Mar; 109(5):2130-8. PubMed ID: 17095620
[TBL] [Abstract][Full Text] [Related]
15. Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts.
Fuller K; Owens JM; Chambers TJ
J Immunol; 1995 Jun; 154(11):6065-72. PubMed ID: 7751648
[TBL] [Abstract][Full Text] [Related]
16. Brain-derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma.
Sun CY; Chu ZB; She XM; Zhang L; Chen L; Ai LS; Hu Y
Int J Cancer; 2012 Feb; 130(4):827-36. PubMed ID: 21400510
[TBL] [Abstract][Full Text] [Related]
17. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T
Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900
[TBL] [Abstract][Full Text] [Related]
18. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
19. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Gai D; Chen JR; Stewart JP; Nookaew I; Habelhah H; Ashby C; Sun F; Cheng Y; Li C; Xu H; Peng B; Garg TK; Schinke C; Thanendrarajan S; Zangari M; Chen F; Barlogie B; van Rhee F; Tricot G; Shaughnessy JD; Zhan F
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35881476
[TBL] [Abstract][Full Text] [Related]
20. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
